Compare BHR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | CGEN |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 191.1M |
| IPO Year | N/A | 2001 |
| Metric | BHR | CGEN |
|---|---|---|
| Price | $2.29 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 662.9K | 240.4K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | ★ 8.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.88 | $1.30 |
| 52 Week High | $3.19 | $3.24 |
| Indicator | BHR | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 61.20 | 53.58 |
| Support Level | $2.19 | $2.22 |
| Resistance Level | $2.61 | $2.54 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 97.14 | 47.06 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.